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Background: Three flea species, Pulex irritans, Ctenocephalides canis and C. felis parasitize shepherd dogs living on
sheep farms in Greece. The aim of this randomized, blinded, placebo-controlled trial was to examine the efficacy of
spinosad, when administered three times every 4 weeks, as the only intervention to treat and prevent flea infesta-
tions in shepherd dogs living on sheep farms.
Methods: Thirty dogs living on sheep farms and infested by at least 24 fleas were randomly allocated into equal
groups. Group A dogs received spinosad (45–70 mg/kg body weight), every 4 weeks for three administrations,
whereas Group B dogs were placebo-treated. Flea counting was performed at the beginning of the trial (day 0) and
after 14, 28, 56 and 84 days. The first five fleas from each dog and 2–6 fleas collected from 5–11 sheep were used
for species identification.
Results: The percentage of dogs with zero flea counts was significantly higher in group A than in group B at days
14, 28, 56 and 84 and flea counts were significantly lower in group A than in group B at days 14, 28, 56 and 84. In
group A, flea counts were significantly lower at days 14, 28, 56 and 84 compared to day 0 whereas there were no
changes in flea counts of group B dogs. The percent efficacy of spinosad for the treatment and prevention of flea
infestation was higher than 98 % (arithmetic means) or higher than 99 % (geometric means) throughout the study.
No adverse reactions were recorded.
C. canis was the predominant flea species of dogs at day 0. In group A the relative abundance of C. felis increased
at day14 whereas in group B the relative abundance of P. irritans increased at days 14, 28, 56 and 84.
Conclusions: Spinosad is safe and effective for the treatment of C. canis and C. felis infestations and for the
prevention of P. irritans, C. canis and C. felis infestations in shepherd dogs living in close proximity to sheep.
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In many areas of the word, fleas are common ectopara-
sites of dogs [1]. They can cause blood loss anemia, flea
bite and flea allergic dermatitis and they are intermedi-
ate hosts of parasites and vectors of bacterial pathogens
of zoonotic importance, such as Bartonella spp. [1, 2].
Ctenocephalides felis is generally considered to be the
most common flea species parasitizing dogs [1]. However,
in Greece, C. canis has been found to be more prevalent* Correspondence: msarido@vet.uth.gr
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creativecommons.org/publicdomain/zero/1.0/than C. felis among dogs admitted to a University Teach-
ing Hospital in the northern part of the country [3]. More
recently, when dogs living on dairy goat and sheep farms
located in central and southern Greece were examined,
the most common flea species found was Pulex irritans,
followed by C. canis and then by C. felis [4]. Also, a high
flea burden has been noticed in some dogs living on sheep
farms in central Greece that have been admitted, for
various reasons, to the author’s University Clinic, prob-
ably because no anti-flea interventions had been used
on the dogs, the sheep or the environment (unpublished
observations).Access article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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after ingestion by the insect during blood meal,
targets their nicotinic acetylcholine receptors and
gamma-aminobutyric acid neurotransmission, leading
to hyperexcitation and death [5–7]. When adminis-
tered orally, spinosad is effective for the treatment of
pre-existing and for the prevention of new infesta-
tions by C. felis and C. canis under laboratory condi-
tions [5, 6, 8–12], by C. felis in a simulated home
environment [13] and by undetermined flea species
under field conditions [5, 14, 15] for up to 4 weeks.
The aim of this randomized, blinded, placebo-controlled
trial was to examine the efficacy of spinosad, when given
every 4 weeks for 3 consecutive administrations, as the
only intervention to treat and prevent flea infestation in
shepherd dogs living on sheep farms in central Greece.Methods
Ethical approval
The experimental protocol was in accordance with the
Greek laws (1197/81 and 2015/92) and had been ap-
proved, on both legal and ethical grounds, by State au-
thorities (license No 2537). Signed informed consent
was obtained from dog/farm owners before enrollment
of the dogs into the study.
In addition to the 1 h post-administration observation
of all dogs by one of the investigators (MKC), owners
were instructed to monitor each dog for the duration of
the study and to report any possible adverse events
whether or not considered to be treatment-related.Study dogs
A total of 30 flea-infested dogs living on sheep farms in
central Greece were enrolled in this study. To be in-
cluded in the study they should present no abnormal-
ities on physical examination (including skin lesions
indicative of flea allergic dermatitis like hypotrichosis,
alopecia, crusts, excoriations, hyperpigmentation,
lichenification in the posterior part of the body), lived
on the same farm with at least one more dog eligible
for the study, had been infested by at least 10 fleas at
the beginning of the trial (day 0) and they should not
have been treated with ectoparasiticides, including
pyrethroid-impregnated collars, for a minimum time
period determined on the product label (e.g. at least
8 months before enrollment for flumethrin-impregnated
collars and 1 month for spot-ons labeled for monthly
use). Dogs younger than 14 weeks of age, with a body
weight of less than 3.9 kg, with pre-existing diseases,
under extra-label treatment with ivermectin for demo-
dectic mange or other ectoparasitoses [7, 16, 17], as
well as pregnant or lactating females were excluded
from the study.Study groups
The dogs were randomly allocated into two groups
(group A and group B). For this purpose, all eligible dogs
living on each farm were considered as a block and per
block randomization was done using a random number
generator software, freely available from the internet
(http://www.random.org/). Group A dogs (n = 15) re-
ceived spinosad (Comfortis; Elanco Animal Health), at
the dose registered in Europe (45–70 mg/kg body
weight) [5], every 4 weeks for three administrations
(Fig. 1). Spinosad was given with food by the owner,
under the supervision of a member of the research
team (MKC) who monitored the dogs for the next
1 h; if vomiting or regurgitation occurred during this
period spinosad administration had to be repeated.
Group B dogs (n = 15) received placebo tablets made
of starch and inert excipients that were administered
in the same way and at the same time intervals as
spinosad in group A dogs (Fig. 1). The trial was con-
ducted from April to July 2014 and no other ectopar-
asiticides were used on the dogs, the sheep or the
environment.
Flea counting and identification
Flea counts were performed at day 0 and after 14, 28, 56
and 84 days (Fig. 1) by another investigator (TP) who
was blinded as to each dog’s group. Dogs were separated
from the flock at least 4 h before (the exact time was
not recorded but it is estimated to range from 4 to 6 h)
and were kept in a near-by open area where flea count-
ing was performed before the administration of spinosad
or placebo. Each dog was combed all over the body with
a fine-tooth flea comb for at least 10 min and until no
fleas could be recovered for the last minute and all live
fleas were captured and counted. The first five fleas were
placed in a separate vial with 90 % ethanol for species
identification, whereas the remaining fleas were tempor-
arily kept in a zip-closing plastic bag and were returned
to the back of the dog at the end of the procedure. At
the same time points, 2–6 fleas were collected manually
from each of 5–11 randomly selected sheep and were
placed in separate vials with 90 % ethanol for species
identification. Species identification of fleas was based
on microscopic examination as described by Wall and
Shearer [18].
Statistical analysis
The sex, age and body weight of the dogs as well as the
number of fleas per dog at day 0 were compared
among the different farms with Fisher’s exact test (sex)
and one-way ANOVA (age, body weight, number of
fleas). Also, the two groups of dogs were compared in
terms of their distribution among the different farms
(Fisher’s exact test) and the sex (χ2 test), age, body
Fig. 1 Design of the study. Time points of flea counting and administration of spinosad (group A dogs) or placebo (group B dogs)
Table 1 Description of the three farms
Farm A Farm B Farm C
Number of sheep 30 43 21
Number of dogs 10 16 4
Number (%) of group A dogs 6 (60 %) 8 (50 %) 1 (25 %)
Spinosad dose (mean ± SD) in mg/kg 57 ± 8.84 55.1 ± 6.89 69.33
Number (%) of group B dogs 4 (40 %) 8 (50 %) 3 (75 %)
Number of sheep in the three farms, number of dogs and allocation of the
dogs into group A (spinosad-treated) and group B (placebo-treated)
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ent samples t-test).
The geometric mean number of fleas for each group
of dogs at the different time points of the study was
calculated after adding 1 to the flea count of each dog,
calculating the natural logarithm of (flea count +1),
calculating the arithmetic mean of these logarithms, calcu-
lating the antilogarithm of the arithmetic mean and sub-
tracting 1 from the antilogarithm. The percent efficacy of
spinosad was calculated at the different time points of the
study, using both the geometric and the arithmetic means
of flea counts, with the formula E ¼ Mc−MtMc  100, where E is
the percent efficacy, Mc the mean (geometric or arith-
metic) flea count in the controls (group B) and Mt the
mean (geometric or arithmetic) flea count in the
spinosad-treated dogs (group A).
The number of dogs with zero flea counts and the flea
counts at the different time points of the study was com-
pared between the two groups with χ2 test and with in-
dependent samples t-test, respectively. At 5 % level of
significance, the power of the study was 80 % to detect a
54 % difference between the two groups in the number
of dogs with zero flea counts and 80 % to detect a 21 %
difference of flea counts between the two groups, assum-
ing a standard deviation of 0.2.
For each group of dogs, flea counts were compared
among all time points of the study with Friedman’s two-
way ANOVA; when a significant difference was found
post-hoc tests (related samples Wilcoxon Signed Rank
test) were used to examine for differences between all
pairs of time points.
The relative abundance of each flea species was cal-
culated as it’s percentage among all fleas identified,
separately for group A dogs, for group B dogs and for
sheep. The relative abundance was compared among
the farms at each time point of the study, for each
farm separately among the time points of the study,
and, after combining the results from all farms,
among the time points of the study with Fisher’s
exact test.
Statistical analysis was done using SPSS 20 for Windows
and the level of significance was set at 5 %.Results
Dogs, group allocation, treatment administration and
adverse events
A total of 30 dogs, living on three different sheep farms
(designated as farms A, B and C) were screened and all
of them were eligible for the study and they completed
the 84 day trial. In farm A there were 10 dogs and 30
sheep, in farm B 16 dogs and 43 sheep and in farm C 4
dogs and 21 sheep (Table 1). All dogs lived mainly out-
doors and had free access to and close contact with
sheep. All 30 dogs were mongrels, they included 16
(53.3 %) intact males and 14 (46.7 %) intact females,
their age ranged from 1 to 7 years (mean ± standard
deviation: 3.15 ± 1.65 years) and their body weight
ranged from 12–50 kg (mean ± standard deviation:
28.53 ± 11.13 kg).
Fifteen dogs (6 from farm A, 8 from farm B and 1
from farm C) were allocated to group A (spinosad) and
15 dogs (4 from farm A, 8 from farm B and 3 from
farm C) were allocated to group B (placebo) (Table 1).
Spinosad dose for group A dogs ranged from 45 to
69.3 mg/kg body weight (mean ± standard deviation:
56.82 ± 8.04 mg/kg body weight). Flea counts at day 0
ranged from 24 to 73 fleas per dog (median: 48; arith-
metic mean: 49.3; geometric mean: 47.1) in group A
and from 31 to 76 fleas per dog (median: 56; arithmetic
mean: 53; geometric mean: 51.1) in group B (Table 2).
No significant differences were found in the distribu-
tion of the two groups of dogs among the 3 farms (P =
0.47) or in their sex (P = 1), age (P = 0.14), body weight
(P = 0.73) and flea counts at day 0 (P = 0.48).
Table 2 Flea counts, number of dogs with zero flea count and percent efficacy of spinosad
Day 0 Day 14 Day 28 Day 56 Day 84
Flea counts
Group A B A B A B A B A B
Range 24-73 31-76 0-4 22-72 0 21-69 0 24-79 0 20-86
Median 48 56 0 46 0 56 0 53 0 64
Arithmetic mean 49.27 53 0.6 47 0 51.27 0 51.33 0 58.67
Geometric mean 47.14 51.05 0.25 44.34 0 48.82 0 48.38 0 54.57
Number (%) of dogs with zero flea counts
Group A (n = 15) 0 (0 %) 12 (80 %) 15 (100 %) 15 (100 %) 15 (100 %)
Group B (n = 15) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Percent efficacy of spinosad
Arithmetic mean 98.72 % 100 % 100 % 100 %
Geometric mean 99.44 % 100 % 100 % 100 %
Range, median, arithmetic and geometric means of flea counts of spinosad-treated (group A) and of placebo-treated (group B) dogs, number of group A and
group B dogs with zero flea counts at the beginning of the trial (day 0) and after 14, 28, 56 and 84 days and percent efficacy of spinosad
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study protocol and no vomiting or other adverse reac-
tions were witnessed throughout the trial.
Flea counts and efficacy of spinosad
Range, median, arithmetic and geometric means of flea
counts of group A and group B dogs at the various time
points of the trial, the number of dogs with zero flea
counts and the percent efficacy of spinosad, based on
both arithmetic and geometric mean of flea counts, are
shown on Table 2.
The percentage of dogs with zero flea counts was sig-
nificantly higher in group A than in group B at days 14
(80 % vs 0 %), 28 (100 % vs 0 %), 56 (100 % vs 0 %) and
84 (100 % vs 0 %; P < 0.001 for all comparisons) and flea
counts were significantly lower in group A than in group
B at days 14, 28, 56 and 84 (P < 0.001 for all compari-
sons). In group A, flea counts were significantly different
among the five time points of the trial (P < 0.001) and
post-hoc testing revealed that they were significantly
lower at days 14 (arithmetic mean: 0.6, geometric mean:
0.25), 28, 56 and 84 (zero arithmetic and geometric
means) compared to day 0 (P < 0.001 for all compari-
sons) without difference between any other time points.
On the contrary, no significant difference was found in
flea counts of group B dogs among the five time points
of the trial (arithmetic means: 47–58.67, geometric
means: 44.34-54.57; P = 0.07).
The percent efficacy of spinosad for the treatment of
pre-existing and the prevention of newly acquired flea
infestations, under the conditions of this trial, was
higher than 98 % (arithmetic means) or higher than
99 % (geometric means) at 14, 28, 56 and 84 days
(Table 2).Species of fleas parasitizing dogs and sheep
Fleas were found on group A (spinosad-treated) dogs at
days 0 and 14 only (Table 2) and C. canis was predomin-
ant over C. felis (Table 3). The relative abundance of
these two flea species did not differ among the three
farms at either day 0 or 14, whereas, the relative abun-
dance of C. felis was higher at day 14 compared to day 0
(P = 0.003).
Fleas were found on group B (placebo-treated) dogs at
all time points (Table 2). C. canis was the most prevalent
flea species at day 0 but thereafter P. irritans predomi-
nated (Table 3). The relative abundance of C. canis was
significantly higher at day 0 compared to days 14, 28, 56
and 84 and at day 14 compared to days 28, 56 and 84,
whereas the opposite was found for P. irritans (P ≤ 0.002
for all comparisons). The only difference (P ≤ 0.001 for
all comparisons) among the three farms was noticed at
day 14 when only P. irritans was found on farm A dogs,
both P. irritans (60.5 %) and C. canis were found on
farm B dogs and both C. canis (80 %) and C. felis (20 %)
were found on farm C dogs. The time that the relative
abundance of C. canis and P. irritans changed also dif-
fered among the farms. In farm A the relative abundance
of C. canis was higher and that of P. irritans was lower
at day 0 compared to all other time points (P < 0.001 for
all comparisons) but there were no differences among
days 14, 28, 56 and 84 (i.e. significant changes occurred
in the first 14 days). In farm B, in addition to the differ-
ences noticed in farm A (P < 0.001 for all comparisons),
the relative abundance of C. canis was lower and that of
P. irritans was higher also at day 14 compared to days
28, 56 and 84 (P ≤ 0.015) and there were no differences
among days 28, 56 and 84 (i.e. significant changes oc-
curred in the first 28 days). Finally, in farm C there was
Table 3 Flea species in group A and group B dogs
Day 0 Day 14 Day 28 Day 56 Day 84
Group A (spinosad)
Ctenocephalidescanis 61/62 (98.4 %) 4/7 (57.1 %) N/A N/A N/A
Ctenocephalidesfelis 1/62 (1.6 %) 3/7 (42.9 %) N/A N/A N/A
Pulexirritans 0/62 (0 %) 0/7 (0 %) N/A N/A N/A
Group B (placebo)
Ctenocephalidescanis 60/62 (96.8 %) 23/68 (33.8 %) 9/69 (13 %) 8/73 (11 %) 7/71 (9.9 %)
Ctenocephalidesfelis 2/62 (3.2 %) 2/68 (2.9 %) 0/69 (0 %) 0/73 (0 %) 0/71 (0 %)
Pulexirritans 0/62 (0 %) 43/68 (63.2 %) 60/69 (87 %) 65/73 (89 %) 64/71 (90.1 %)
Relative abundance of each flea species on spinosad-treated (group A) and placebo-treated (group B) dogs at the beginning of the trial (day 0) and after 14,28, 56
and 84 days
N/A: non-applicable (due to zero flea counts)
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decrease on C. canis and a significant increase of P. irri-
tans relative abundance was found in the comparisons
between day 0 and days 28, 56 and 84 (P < 0.001 for all
comparison) as well as between day 14 and days 28, 56
and 84 (P < 0.001 for all comparison) (i.e. significant
changes occurred between 14 and 28 days).
Fleas were found on sheep at all time points. P.
irritans predominated (>88.9 %), followed by C. canis
(0–18.2 %) and C. felis (0–5.6 %). There were no sig-
nificant differences among the three farms but the
comparison among time points showed increased
prevalence of C. canis at day 28 (P = 0.037) and day 84
(P = 0.031) compared to day 0.
Discussion
The high percent efficacy of spinosad for the treatment
and prevention of flea infestations (>98 % and >99 %
using arithmetic and geometric means, respectively) is
comparable to the efficacy of this molecule that has been
reported in most studies where dogs were experimen-
tally infested by C. canis [10] or C. felis [5, 6, 9, 19], as
well as after experimental infestation with C. felis of dogs
in a home simulated environment [13]. Also, the reduc-
tion of flea counts witnessed in the present study was
very similar to those reported previously in field trials of
spinosad [5, 14, 15], spinosad-milbemycin oxime com-
bination [20] and spinosad in combination with an ami-
traz collar [21]. Finally, the prevalence of spinosad-
treated dogs with zero flea counts (80-100 %) is similar
to that reported after experimental infestation by C. felis
[19] or C. canis [10] and in field trials of spinosad alone
[14] or spinosad-milbemycin oxime combination [20].
However, at least for some time points of this study,
these figures seem to be higher compared to other field
trials testing either spinosad alone [5] or spinosad in
combination with an amitraz collar [21].
The separation of the dogs from the flock before flea
counting as well as the duration of combing may haveled to an overestimation of the percent efficacy of spino-
sad, of the prevalence of dogs with zero flea counts and/
or of the flea count reductions in spinosad-treated dogs.
All dogs were removed from the, presumably heavily
infested, premises to a nearby open area for at least 4 h
before flea counting in order to avoid, as much as pos-
sible, infestations by newly-emerged fleas. The 4 h time
period was selected based on the results of experimental
infestations showing that, due to the fast action of spino-
sad, a therapeutic efficacy of 80-100 % is anticipated at
4 h, at least for the first 2 weeks after drug administra-
tion and because this time is adequate for most newly
acquired fleas to a blood meal [9, 10]. Although the
separation from the flock is somehow similar to the
movement of household dogs to a research facility for
flea counting [14], it is logical to assume that
spinosad-treated dogs experienced transient flea infes-
tations during their normal daily routine in the farms.
The duration of flea combing (at least 10 min and
until no fleas were recovered for the last minute) used
in the present study was in the range proposed by the
recent guidelines of the World Association for the
Advancement of Veterinary Parasitology [22]. How-
ever, it cannot be excluded that a lower prevalence of
dogs with zero flea counts would have been recorded
among spinosad-treated dogs if longer combing pe-
riods had been selected, like in some previous field
trials [5, 14, 21].
On the other hand, the flea counts at the beginning
of the present study (geometric mean in group A dogs:
47.14) was higher compared to most previously pub-
lished field trials of spinosad or spinosad-milbemycin
oxime combination (geometric means of spinosad
treated dogs: 16.4 to 40.7) [5, 20, 21] and this is the
only field study where a placebo group has been used.
Furthermore, besides the placebo-treated group B
dogs, there were additional untreated flea hosts (i.e.
sheep) and no environmental control measures were
applied. For these reasons, the >98 % efficacy and the
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throughout this 3-month trial are particularly impressive.
Three flea species, P. irritans, C. canis and C. felis,
were recovered from the sheep and there was a clear
predominance of P. irritans throughout this trial
whereas, in a previous study, P. irritans was the only
species found in sheep living on dairy goat farms in cen-
tral and southern Greece [4]. Surprisingly, P. irritans
was not found in any group A or group B dog at day 0,
whereas this species has been reported to predominate
over C. canis and C. felis when 54 dogs living on dairy
goat farms, with or without sheep, were examined [4].
This discrepancy may be explained by: a) the absence of
goats, which are highly preferred hosts and heavily
infested by P. irritans [4], in the three farms of our
study; b) temporal differences (the previous study was
conducted in June and July whereas the present study
started in April); and c) the collection of only 5 fleas per
dog (i.e. 6.6-20.1 % of the total flea burden) for species
identification which was done in an effort to minimize
interference with future flea counts [22]. Therefore, al-
though it cannot be excluded that some dogs may have
been infested by P. irritans at the beginning of the trial,
it seems that C. canis shows a particular preference for
these hosts.
There are two, non-mutually exclusive, explanations
for the significant change in favor of P. irritans that was
witnessed in placebo-treated (group B) dogs during this
trial, namely a seasonal effect and an effect of spinosad
treatment of group A dogs. At least in goats, the inten-
sity of infestation by P. irritans has been shown to in-
crease steadily from May to June [4] and if the same
applies for the dogs it could explain the increasing rela-
tive abundance of this species from the beginning (April)
towards the end (July) of the present study. However,
the increased relative abundance of C. canis in sheep at
days 28 and 84 does not seem to be in favor of this
explanation. The fast adult flea killing activity of spi-
nosad has a strong negative impact on egg production
so that new adult flea emergence progressively de-
clines when all dogs (and obviously other possible
hosts) are treated [9, 12, 13]. In our study, adminis-
tration of spinosad in some of the dogs in each farm
may have reduced the relative abundance of C. canis,
which was the predominant flea species at day 0, thus
leading to an increased relative abundance of P. irri-
tans. The observation that this change occurred earl-
ier in farm A (60 % of the dogs received spinosad)
than in farm B (50 % of the dogs received spinosad)
and even later in farm C (25 % of the dogs received
spinosad) is in favor of this explanation.
Vomiting is the most common adverse reaction of spi-
nosad that has been recorded in both experimental stud-
ies and field trials [9, 19]. In the present study, neithervomiting nor any other adverse reactions were recorded,
confirming the high tolerance of this molecule.
Conclusions
When administered at 45–69.3 mg/kg body weight every
4 weeks for three times in shepherd dogs living in close
proximity to sheep, the efficacy of spinosad for the treat-
ment of infestations by at least two flea species (C. canis
and C. felis) and for the prevention of infestations by P.
irritans, C. canis and C. felis was 98.7 % (arithmetic
means) or 99.4 % (geometric means) at 14 days and
100 % thereafter. The efficacy of this molecule is further
supported by the number of treated dogs with zero flea
counts (80 % at 14 days and 100 % thereafter). The re-
sults demonstrate that spinosad is safe and effective for
the treatment and prevention of flea infestation in shep-
herd dogs living in close proximity to sheep.
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